LONDON -- The European Medicines Agency on Friday recommended authorizing Moderna’s COVID-19 vaccine for children ages 12 to 17, the first time the shot has been authorized for people under 18.
The EU drug regulator said research in more than 3,700 children aged 12 to 17 showed that the Moderna vaccine — already given the OK for adults across Europe — produced a comparable antibody response.
Until now, the vaccine made by Pfizer and German partner BioNTech has been the only option for children as young as 12 in North America and Europe.
The U.S. Food and Drug Administration is currently considering whether to extend the use of the Moderna vaccine to the same age group.
With global vaccine supplies still tight, much of the world is struggling to immunize adults. The World Health Organization and other agencies have urged rich countries to donate their doses to the developing world — where fewer than 2% of people have been vaccinated — rather than moving on to inoculate their less vulnerable populations.
Hundreds of millions of Moderna doses already have been administered to adults, and the company says the two-dose vaccine is just as protective for adolescents. In a study of more than 3,700 12- to 17-year-olds, the vaccine triggered the same signs of immune protection, and no COVID-19 diagnoses arose in the vaccinated group compared with four cases among those given dummy shots.
Sore arms, headache and fatigue were the most common side effects in the young vaccine recipients, the same ones as for adults.
U.S. and European regulators caution, however, that both the Moderna and Pfizer vaccines appear linked to an extremely rare reaction in teens and young adults — chest pain and heart inflammation.
In the United States, children represent about 14% of the nation’s total coronavirus cases to date. And while the young are far less likely than the old to get seriously ill, at least 344 children have died of COVID-19 in the U.S. alone, according to a tally by the American Academy of Pediatrics.
So far in the U.S., just under half the population is fully vaccinated — with the highest rates, not surprisingly, among older adults. Just a quarter of 12- to 15-year-olds, who got access to Pfizer’s vaccine starting in May, have had their second dose, according to the Centers for Disease Control and Prevention. Among those 16 and 17, about 37% are fully vaccinated.
Both Pfizer and Moderna have begun testing in even younger children, from age 11 down to 6 months old. These studies are more complex: Teens receive the same dose as adults, but researchers are testing smaller doses in younger children. The first results from children of elementary school age are expected in September.
The EU drug regulator said it would continue to monitor the safety and efficacy of the Moderna vaccine in children as it is used in European member countries.
Although some countries have authorized Pfizer-BioNTech's vaccine for children under 18, not all have decided to start using it, citing the minimal risks children face from the coronavirus.
In Britain, for example, regulator cleared Pfizer's vaccine for 12 to 15-year-olds, but health officials have so far declined to recommend the vaccine for anyone under 18 unless they have medical conditions that warrant it.
Neergaard reported from Alexandria, Virginia.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.